Ownership and insider activity for Denali Therapeutics Inc. (DNLI): recent transactions by executives and directors. Track how corporate insiders are trading the stock.
Denali Therapeutics Inc. is a biopharmaceutical firm, founded in 2013 and based in South San Francisco, California, which focuses on identifying and advancing treatments for neurodegenerative conditions within the United States. The company, initially known as SPR Pharma Inc. until its renaming in March 2015, possesses a robust development pipeline.
Price
| Price | $18.86 (closing price, November 2, 2026) |
| Market Cap | $3.0B |
| Exchange | NASDAQ |
| Country | US |
Recent Insider Transactions
| Date | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 2026-09-04 | Chin Peter Scott | S-Sale | 1,654 | $37K |
| 2026-09-02 | Thornberry Nancy | S-Sale | 10,824 | $247K |
| 2026-09-02 | Thornberry Nancy | S-Sale | 615 | $15K |
| 2026-09-01 | Schuth Alexander O. | S-Sale | 2,768 | $65K |
| 2026-08-12 | Watts Ryan J. | G-Gift | 32,220 | |
| 2026-08-11 | Schuth Alexander O. | S-Sale | 2,857 | $72K |
| 2026-06-03 | FLATLEY JAY T | A-Award | 6,408 | |
| 2026-06-03 | FLATLEY JAY T | A-Award | 19,226 | $378K |
| 2026-06-03 | Klein Peter S | A-Award | 6,408 | |
| 2026-06-03 | Klein Peter S | A-Award | 19,226 | $378K |
Balance Sheet (10y)
| Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $39.9M | $218.4M | $77.1M | $79.4M | $507.1M | $293.5M | $218.0M | $127.1M | $175.0M | $205.3M |
| Short-term Investments | $138.5M | $187.9M | $387.2M | $335.9M | $962.6M | $571.9M | $1.12B | $907.4M | $657.4M | $662.6M |
| Receivables | $438,000 | $464,000 | $8.5M | 0 | 0 | $1.2M | $9.3M | $3.4M | $2.2M | $2.2M |
| Inventory | 0 | -$464,000 | -$8.5M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Current Assets | $182.0M | $409.6M | $480.8M | $430.0M | $1.50B | $897.2M | $1.37B | $1.06B | $864.4M | $900.7M |
| Property, Plant & Equipment | $15.3M | $14.9M | $25.2M | $80.7M | $73.5M | $69.6M | $74.5M | $71.6M | $125.6M | $119.9M |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Assets | $271.1M | $486.7M | $662.0M | $553.2M | $1.60B | $1.40B | $1.46B | $1.15B | $1.37B | $1.14B |
| Accounts Payable | $2.0M | $2.7M | $1.9M | $2.6M | $1.1M | $4.8M | $2.8M | $9.5M | $11.1M | $3.3M |
| Short-term Debt | 0 | 0 | 0 | 0 | $4.7M | 0 | 0 | 0 | 0 | 0 |
| Total Current Liabilities | $9.1M | $14.2M | $32.8M | $45.3M | $71.7M | $378.2M | $363.9M | $78.0M | $102.2M | $98.4M |
| Long-term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Liabilities | $16.5M | $20.9M | $115.1M | $158.3M | $453.7M | $441.9M | $417.8M | $123.0M | $144.5M | $131.1M |
| Retained Earnings | -$103.5M | -$191.7M | -$227.9M | -$425.6M | -$354.4M | -$645.0M | -$971.0M | -$1.12B | -$1.54B | -$2.05B |
| Total Equity | $254.5M | $465.8M | $546.8M | $394.9M | $1.15B | $962.3M | $1.04B | $1.03B | $1.23B | $1.01B |
| Total Debt | 0 | 0 | 0 | $72.5M | $68.9M | $64.0M | $60.4M | $52.2M | $48.7M | $36.8M |
| Net Debt | -$178.3M | -$406.2M | -$464.3M | -$342.8M | -$1.40B | -$801.4M | -$1.28B | -$982.3M | -$783.6M | -$831.1M |
| Working Capital | $172.8M | $395.4M | $448.1M | $384.7M | $1.42B | $519.0M | $1.01B | $986.2M | $762.2M | $802.3M |
Financial Health
| Debt / Equity | 0.03 |
| Current Ratio | 8.37 |
| Piotroski F-Score | 2 |
| Altman Z-Score | 9.99 |
Profitability
| Return on Equity | -55.27% |
| Return on Invested Capital | -50.82% |
| Return on Assets | -44.17% |
| Gross Margin | -61.04% |
| Operating Margin | -15,058.19% |
| Net Margin | -14,191.20% |
Related companies: NBIX · IONS · PRAX · AMLX · BHVN
Explore sector: Healthcare · Biotechnology
More sections of DNLI: Overview · Financials · Valuation · Statistics · Estimates · Technical · News · Events
Discover more: Weekly Radar: the S&P 500 through the Buffett and Lynch methods · Companies that pass the Buffett method · Companies that pass the Lynch method · Stocks that pass Graham's defensive investor test today · Investment Academy — learn to analyze stocks